4D Molecular Therapeutics (FDMT) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

FDMT · Stock Price

USD 9.93+6.85 (+222.40%)

Market Cap: $502.9M

Historical price data

Overview

4D Molecular Therapeutics is a platform-driven gene therapy company leveraging its proprietary Therapeutic Vector Evolution (TVE) platform to engineer optimized AAV vectors for specific diseases. The company has advanced two lead programs into Phase 3 for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), demonstrating significant reductions in treatment burden, and has a Phase 1/2 program in cystic fibrosis. Its strategy focuses on large markets with high unmet need, validated by strategic partnerships with Astellas and Otsuka, and funding from the Cystic Fibrosis Foundation.

OphthalmologyPulmonology

Technology Platform

Therapeutic Vector Evolution (TVE) platform applies directed evolution to engineer novel AAV capsids with enhanced tissue targeting, reduced immunogenicity, and improved manufacturability for gene therapies.

Pipeline

9

9 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 ...	Neovascular Age-Related Macular Degeneration (nAMD)	Phase 3
4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 ...	Macular Neovascularization Secondary to Age-Related Macular Degeneration	Phase 3
4D-150 IVT + Aflibercept IVT	Diabetic Macular Edema	Phase 2
4D-710	Cystic Fibrosis Lung	Phase 2
4D-150 IVT + Aflibercept IVT	Neovascular (Wet) Age-Related Macular Degeneration	Phase 1/2

Opportunities

Lead asset 4D-150 targets multi-billion dollar markets in wet AMD and DME with potential to drastically reduce treatment burden.

The inhaled gene therapy 4D-710 addresses an unmet need in cystic fibrosis patients ineligible for modulators.

The TVE platform offers long-term value through vector licensing deals in ophthalmology, CNS, and beyond.

Risk Factors

High clinical risk associated with ongoing Phase 3 trials for 4D-150.

Potential for immune-related adverse events common to AAV gene therapies.

Future commercialization challenges in crowded anti-VEGF markets and with high-cost, one-time therapies.

Competitive Landscape

Faces competition in ophthalmology from Adverum, Regenxbio/AbbVie, and Gyroscope/Novartis. In cystic fibrosis, competes with Vertex, Spirovant, and ReCode. As an AAV platform, competes with Dyno Therapeutics and others in AI/ML-driven capsid engineering.

More companies in Cell & Gene Therapy →More companies in United States →